METROGEL (metronidazole) by Galderma is 12. First approved in 1988.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
METROGEL is a topical metronidazole gel approved in 1988 for the treatment of rosacea, a chronic inflammatory skin condition. The exact mechanism of action in rosacea remains unknown, though metronidazole is thought to have anti-inflammatory properties. This small-molecule topical agent delivers minimal systemic exposure when applied to facial lesions.
Mature product approaching loss of exclusivity with minimal commercial scale; expect focus on cost containment and brand defense rather than team expansion.
12.1 Mechanism of Action The mechanism of action of metronidazole in the treatment of rosacea is unknown. 12.2 Pharmacodynamics The pharmacodynamics of metronidazole in association with the treatment of rosacea are unknown. Cardiac Electrophysiology: The effect of METROGEL on the QTc interval has…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Worked on METROGEL at Galderma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moMETROGEL positions you in a defensive, mature-market environment where success depends on cost management, market share retention, and stakeholder relationship strength rather than innovation or growth. This is ideal for professionals seeking stability in a niche indication but offers limited long-term career trajectory given LOE proximity.